Aspartylglucosaminuria is a condition that primarily affects mental functioning and movement. This conditions worsens over time. Infants with aspartylglucosaminuria appear healthy at birth, and development is typically normal throughout early childhood. Around the age of 2 or 3, affected children usually begin to have delayed speech, mild intellectual disability, and problems coordinating movements. Other features that develop in childhood include respiratory infections, a protrusion of organs through gaps in muscles (hernia), and a growth spurt resulting in a large head size (macrocephaly).
Variants (also known as mutations) in the AGA gene cause aspartylglucosaminuria. The AGA gene provides instructions for producing an enzyme called aspartylglucosaminidase. This enzyme is active in lysosomes, which are structures inside cells that act as recycling centers. Within lysosomes, the enzyme helps break down complex chains of sugar molecules (oligosaccharides) attached to certain proteins (glycoproteins).
In Finland, it is estimated that 1 to 3 individuals are born with aspartylglucosaminuria each year. This condition is less common outside of Finland, but the incidence is unknown.
This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have variants. The parents of an individual with an autosomal recessive condition each carry one copy of the altered gene, but they typically do not show signs and symptoms of the condition.
Antje Banning is in Giessen, Germany. Banning is rated as an Elite expert by MediFind in the treatment of Aspartylglucosaminuria. She is also highly rated in 9 other conditions, according to our data. Her top areas of expertise are Aspartylglucosaminuria, CLN2 Disease, CLN4 Disease, and Neuronal Ceroid Lipofuscinoses.
Ritva Tikkanen is in Giessen, Germany. Tikkanen is rated as a Distinguished expert by MediFind in the treatment of Aspartylglucosaminuria. They are also highly rated in 4 other conditions, according to our data. Their top areas of expertise are Aspartylglucosaminuria, Succinic Semialdehyde Dehydrogenase Deficiency, CLN5 Disease, and CLN1 Disease.
Taina Autti is in Helsinki, Finland. Autti is rated as a Distinguished expert by MediFind in the treatment of Aspartylglucosaminuria. She is also highly rated in 7 other conditions, according to our data. Her top areas of expertise are Aspartylglucosaminuria, CLN5 Disease, CLN1 Disease, and CLN2 Disease.
Published Date:updated Last, January
Published By: National Institutes of Health